AI주식인사이트AI Stock Insight
C

바이넥스

053030KOSDAQ

47.0 / 100

Reference Date: 2026-10-23

Financial Score16.5 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 3.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Bionex is a biopharmaceutical CDMO company that produces chemical pharmaceuticals at its Busan factory and expanded production capacity threefold with a new facility in 2023. Its chemical business unit focuses on ointments and eye drops, securing market share with proprietary products, while biopharmaceutical CDMO services accounted for 46.72% of revenue in 2025. The company has established cGMP-compliant systems and passed global GMP inspections to grow as a global CDMO.

Number of Employees

791people

Average Salary

49.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
1.07Industry Average 1.204.0Point

In line with industry avg

ROE
-1.78Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
32.71Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲6.8% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼1482.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -6.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 6,140Won52-week high 16,40052-week low 5,690
1-month return2.0Point

1m -3.15% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 1Neutral 2Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-10-16
  • Neutral[기재정정]반기보고서 (2026.06)2026-10-14
  • Positive[기재정정]단일판매ㆍ공급계약체결2026-09-30